Migraine Drugs Market Size & Share 2024 – 2032

Migraine drugs Market Size

Migraine Drugs Market size was valued at USD 6.2 billion in 2023 growing at a CAGR of 6.7% from 2024 and 2032, driven by factors such as the rising prevalence of migraine. This can be attributed to factors such as stress, lifestyle changes, and dietary habits.

For instance, as per the report published by World Health Organization, it has been reported that globally, headache disorders affect approximately 40% of the population, or 3.1 billion people in 2021, and are more common in females compared to males. Migraine is among the top three most common neurological conditions for most age groups.
 

Similarly, as per an article published in National Library of Medicine, it has been reported that India and China collectively accounted for over 25% of global migraine cases, while also contributing substantially to tension-type headache (TTH) prevalence. Thus, the rapid increase in the prevalence of migraine globally is the major factor that is expanding the treatment landscape for migraine and is anticipated to foster the growth of the market.
 

Migraine drugs are medications specifically designed to treat or prevent migraines, a type of headache characterized by intense, throbbing pain, often accompanied by nausea, vomiting, and sensitivity to light and sound. The drugs used in migraine can be categorized into two main groups, pain-relieving medication and preventive medication. Further, a migraine headache is caused by abnormal activities of brain observed or measured through brain monitoring devices.
 

Migraine Drugs Market Trends

• Migraine is a common neurological condition that affects a substantial portion of the population, leading to a greater need for therapeutic options. The global rise in the number of people suffering from migraines significantly drives the demand for effective treatments, that is anticipated to propel the growth of the market.
   
• For instance, as per the American Migraine Foundation, it has been estimated that at least 39 million Americans live with migraine. This rising number of reported migraine cases, coupled with increased awareness of the disease's fatal nature has led to a growing demand for effective drug therapies, thereby driving market growth.
   
• Moreover, innovations in drug discovery and development, including new classes of migraine medications such as CGRP (calcitonin gene-related peptide) inhibitors, have provided more effective treatment options, attracting both patients and healthcare providers, further boosting the market for migraine drugs.
   

Migraine Drugs Market Analysis 

Based on the drug class, the global market is classified into pain relieving medication and preventive medication. The pain-relieving medication segment dominated the market with revenue of USD 4.2 billion in 2023.
 

• Triptans are highly effective in aborting acute migraine attacks. Their efficacy in reducing symptoms and improving the patient outcome, makes them a preferred choice.
   
• Also, advancements in drug formulations, such as fast-acting tablets, nasal sprays, or dissolvable films, appeal to patients looking for quick relief from migraine symptoms. Novel drug delivery systems enhance convenience and paient compliance, thereby contributing to the growth of the market.
   
• Furthermore, innovations in drug delivery systems offer convenient and efficient ways to administer pain-relieving medications. These advancements enhance patient compliance and satisfaction, thereby driving market growth.
   

Learn more about the key segments shaping this market

Download Free PDF

Based on the route of administration, the global migraine drugs market is classified into oral, injectable, nasal, and transdermal. The oral segment dominated the market with market share of 49.6% in 2023.
 

• The introduction of novel therapeutic agents including triptans, and CGRP (calcitonin gene-related peptide) inhibitors, enhances the treatment landscape. These new drugs often come in oral formulations. Also, several patients prefer oral dosage forms over injectable or other invasive treatments due to convenience, ease of administration, and reduced discomfort. This preference drives demand for oral migraine medications, thereby contributing to the high segmental growth.
   
• Furthermore, the increased awareness of migraine symptoms and the availability of diagnostic tools lead to earlier and more accurate diagnoses. This awareness drives the demand for effective treatment options including oral medications, thereby fuelling the market growth.
   

Based on types, the migraine drugs market is classified into prescription drugs and OTC drugs. The OTC drugs segment is expected to exhibit 7% CAGR between 2024 - 2032.
 

• There is a growing trend of self-medication, driven by the convenience and accessibility of over-the-counter drugs. Many individuals prefer managing mild to moderate migraine attacks without the need for a prescription, thus boosting the OTC market.
   
• Moreover, regulatory bodies such as U.S. FDA and EMA approving more migraine medications for OTC sale. This regulatory support helps in expanding the market as more products become accessible without the need for a prescription.
   
• Furthermore, OTC migraine drugs are often less expensive compared to prescription medications. This affordability makes them attractive to individuals who may not have health insurance coverage or who are looking to save on healthcare costs. Such factor is expected to spur the segmental growth.
   

Based on distribution channel, the migraine drugs market is classified into hospital pharmacies, drug store & retail pharmacies, and online pharmacies. The hospital pharmacies segment dominated the market in 2023 and is anticipated to reach USD 4.9 billion by 2032.
 

• As migraine prevalence rises, hospitals see a surge in patient visits for migraine treatment. This necessitates well-stocked pharmacies within hospitals to meet the demand for migraine drugs.
   
• Also, hospital pharmacies offer specialized care for complex migraine cases. They stock a wide range of drugs including those for acute attacks, preventive treatment, and rescue medications, catering to varying patient needs.
   
• Furthermore, few of migraine patients require hospitalization for severe attacks or complications. Therefore, hospital pharmacies play a vital role in managing inpatient medication regimens, ensuring proper dosing and administration.
   

In 2023, North America secured a substantial market share of 41.5% in the global migraine drugs market and is expected to dominate throughout the forecast period.
 

• North America boasts advanced healthcare infrastructure and a well-established pharmaceutical industry. This facilitates the development, approval, and distribution of migraine drugs, leading to increased accessibility for patients.
   
• Moreover, growing awareness campaigns and initiatives regarding migraines in North America have led to increased diagnosis rates. As more individuals become aware of their migraine conditions, there is a corresponding rise in demand for migraine medications, thereby boosting the market growth.
   
• Furthermore, North America witnesses substantial healthcare expenditure, both by individuals and governments. This enables patients to afford expensive migraine medications and therapies, thereby fueling the regional market growth.
   

Germany to experience the highest growth rate in the Europe market.
 

• Germany boasts a robust healthcare infrastructure, with a well-established network of hospitals, clinics, and pharmacies. This facilitates the easy distribution and access to migraine drugs, thereby driving migraine drugs market growth.
   
• Moreover, Germany's healthcare system is supported by government policies and health insurance schemes that often cover the cost of migraine treatments. Thus, favorable reimbursement policies encourage patients to seek treatment and alleviate the financial burden associated with migraine management. Such aforementioned factor is expected to augment the country level market growth.
   

The Asia Pacific migraine drugs market is expected to grow with a significant CAGR of 7.1% during the forecast period.
 

• Rapid urbanization and changing lifestyles often lead to higher stress levels, irregular eating habits, and sedentary lifestyles, all of which are contributing factors to migraines. Thus, as urban populations grow in the region, so does the demand for migraine relief medications.
   
• Moreover, with increasing disposable incomes in countries such as China and India, there's a rise in healthcare expenditure, enabling more people to afford migraine medications.
   
• Furthermore, the pharmaceutical industry in the Asia-Pacific region is expanding, driven by advancements in research and development, as well as favorable government policies promoting healthcare infrastructure. This growth facilitates the availability and accessibility of migraine drugs, thereby contributing to the growth of the market in this region.
   

Migraine Drugs Market Share

The competitive landscape of the migraine drugs industry is characterized by the presence of established pharmaceutical companies that manufacture migraine drugs products vying for market share. Key players are engaging in strategic initiatives such as collaboration, product launch, investment, and partnerships to strengthen their product portfolio. The companies are actively adopting a multi-pronged approaches to address the rising demand for migraine drugs.
 

Migraine Drugs Market Companies

Prominent players operating in the migraine drugs industry are as mentioned below:

• AbbVie Inc.
• Amgen, Inc.
• Astellas Pharma
• AstraZeneca Plc
• Azurity Pharmaceutical, Inc.
• Dr. Reddy’s Laboratories, Inc.
• Eli Lilly and Company
• Endo Pharmaceuticals, Inc.
• GlaxoSmithKline Plc
• Lannett Company, Inc.
• Lundbeck A/S
• Pfizer, Inc.
• Sanofi SA
• Sun Pharmaceutical Industries Limited
• Teva Pharmaceutical Industries Limited
   

Migraine Drugs Industry News:

• In May 2023, Pfizer Inc. announced the U.S. Food and Drug Administration (FDA) approved ZAVZPRET (zavegepant), the first and only calcitonin gene-related peptide (CGRP) receptor antagonist nasal spray for the acute treatment of migraine with or without aura in adults. This approval aimed to broaden the treatment availability, complementing existing drug therapies for migraine.  
   
• In April 2023, AbbVie announced that the U.S. Food and Drug Administration (FDA) approved QULIPTA (atogepant) for the preventive treatment of migraine in adults. This helped the company to expand its product offerings.
   

The migraine drugs market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 - 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Drug Class

• Pain relieving medication
  • Triptans
  • Analgesics
  • Ditans
  • Other pain-relieving medications
• Preventive medication
  • Anticonvulsant
  • Antidepressant
  • Beta blocker
  • CGRP inhibitors
  • Other preventive medications

Market, By Route of Administration

• Oral
• Injectable
• Nasal
• Transdermal

Market, By Type

• Prescription drugs
• OTC drugs

Market, By Distribution Channel

• Hospital pharmacies
• Drug store & retail pharmacies
• Online pharmacies

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • South Africa
  • Saudia Arabia
  • UAE
  • Rest of Middle East and Africa